Comparative Pharmacology
Head-to-head clinical analysis: ILOSONE versus PEDIAMYCIN 400.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ILOSONE versus PEDIAMYCIN 400.
ILOSONE vs PEDIAMYCIN 400
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin (ILOSONE) binds to the 50S subunit of bacterial ribosomes, inhibiting peptide chain elongation and protein synthesis by blocking translocation.
Erythromycin binds to the 50S subunit of the bacterial ribosome and inhibits protein synthesis by blocking the translocation step.
Erythromycin (Ilosone) base or stearate: 250-500 mg orally every 6 hours. Estolate: 250-500 mg orally every 6 hours. Maximum dose 4 g/day.
400 mg orally every 6 hours for 10 days.
None Documented
None Documented
1.5-2 hours in adults; prolonged in hepatic impairment (up to 5-6 hours)
1.5-2 hours; prolonged in renal impairment (up to 6 hours)
Renal (2-5% unchanged), biliary/fecal (majority, >90% as metabolites and unchanged drug)
Renal (80-90% unchanged); biliary/fecal (minor, <5%)
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic